Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aziridine SCHEMBL3519414 | 1.00 | — | — | |
| Aziridine SCHEMBL5065556 | 1.00 | — | — | |
| Piperazine SCHEMBL886864 | 0.93 | — | — | |
| Piperazine SCHEMBL632421 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL15855950 | 0.93 | HIF1A (0.86) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Aziridine SCHEMBL16878816 | 0.91 | — | — | |
| Aziridine SCHEMBL2267 | 0.91 | — | — | |
| Aziridine SCHEMBL3089497 | 0.91 | — | — | |
| Piperazine SCHEMBL5380983 | 0.87 | — | — | |
| Piperazine SCHEMBL10945900 | 0.87 | HIF1A (0.75) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653236-B2 | Therapeutic agents | INTER-K PTY LIMITED (AU) | 2014-02-18 | — | — | US | disclosed |
| US-20120277161-A1 | INHIBITION OF MULTIPLE CELL ACTIVATION PATHWAYS | INTER-K PTY LIMITED (AU) | 2012-11-01 | — | — | US | disclosed |
| US-20120244123-A1 | THERAPEUTIC AGENTS | INTER-K PTY LIMITED (AU) | 2012-09-27 | — | — | US | disclosed |
| EP-2454276-A1 | THERAPEUTIC AGENTS | Nutripep Pty Limited (AU) | 2012-05-23 | — | — | EP | disclosed |
| US-20110105408-A1 | THERAPEUTIC PEPTIDES | INTER-K PTY LIMITED (AU) | 2011-05-05 | — | — | US | disclosed |
| EP-2254901-A1 | THERAPEUTIC PEPTIDES | Inter-K Pty Limited (AU) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010094085-A1 | INHIBITION OF MULTIPLE CELL ACTIVATION PATHWAYS | INTER-K PTY LIMITED (AU) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010006377-A1 | THERAPEUTIC AGENTS | NUTRIPEP PTY LIMITED (AU) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009103127-A1 | THERAPEUTIC PEPTIDES | INTER-K PTY LIMITED (AU) | 2009-08-27 | — | — | WO | disclosed |
| US-20080306007-A1 | AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS | NEWCASTLE INNOVATION LIMITED (AU) | 2008-12-11 | — | — | US | disclosed |
| WO-2008098308-A1 | AGENTS AND METHODS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES AND CONDITIONS | NEWCASTLE INNOVATION LIMITED (AU) | 2008-08-21 | — | — | WO | disclosed |